Avidity Partners Management LP Akero Therapeutics, Inc. Transaction History

Avidity Partners Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$11.38 - $50.33 $5.74 Million - $25.4 Million	-504,100 Reduced 68.2%	235,000 $5.49 Million
Q3 2023 Nov 14, 2023	SELL	$41.19 - $52.25 $11.8 Million - $14.9 Million	-285,900 Reduced 27.89%	739,100 $37.4 Million
Q2 2023 Aug 14, 2023	SELL	$36.89 - $56.88 $52.5 Million - $80.9 Million	-1,422,000 Reduced 58.11%	1,025,000 $47.9 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $50.24 $51.4 Million - $69.2 Million	-1,378,000 Reduced 36.03%	2,447,000 $93.6 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $23.5 Million - $38.5 Million	703,000 Added 22.52%	3,825,000 $210 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $31.7 Million - $106 Million	3,122,000 New	3,122,000 $106 Million

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.45B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.